Stifel Nicolaus analyst Clémence Thiers maintained a Buy rating on Nanobiotix today and set a price target of €25.00. The company’s shares opened today at €18.10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Thiers is a 4-star analyst with an average return of 22.7% and a 32.00% success rate.
Nanobiotix has an analyst consensus of Strong Buy, with a price target consensus of €22.00, implying a 21.55% upside from current levels. In a report released on October 6, Jefferies also maintained a Buy rating on the stock with a €21.00 price target.
0QAV market cap is currently €887.6M and has a P/E ratio of -24.77.
Read More on GB:0QAV:
Disclaimer & DisclosureReport an Issue
- Nanobiotix price target raised to EUR 20 from EUR 13 at H.C. Wainwright
- Nanobiotix presents data from JNJ-1900 dose escalation, expansion study cohorts
- Nanobiotix price target raised to EUR 13 from EUR 10 at H.C. Wainwright
- Nanobiotix price target raised to $14 from $9 at Leerink
- Nanobiotix announces new results from JNJ-1900 study
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
